Pakistan may be first to introduce C-IVIG therapy to treat COVID-19
Published On
Pakistan may be first to introduce C-IVIG therapy to treat COVID-19
ISLAMABAD (APP) - Pakistan is on the threshold of becoming the first country to carry out the research, mandatory to introduce intravenous immunoglobulin (C-IVIG) therapy at a mass level as ‘severe’ patients under treatment for coronavirus, have 100 percent recovery rate.
This was pointed out by scientists at Karachi’s Dow University of Health Sciences (DUHS), who are conducting clinical trials of intravenous immunoglobulin (C-IVIG) therapy for the treatment coronavirus.
The therapy uses immunoglobulin (IG), a blood product extracted from the plasma of people who have recovered from infection, and which is rich in the antibodies that target the virus. Continuous infusion of immunoglobin can neutralize the infection in patients and shorten the course of the disease, scientists at DUHS said.
Liminal BioSciences Announces First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras
News provided by
Share this article
Share this article
LAVAL, QC, and CAMBRIDGE, England, Dec. 15, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ( Liminal BioSciences or the Company ), a clinical-stage biopharmaceutical company, today announced that the first subject has been dosed in the Company s fezagepras Phase 1 multiple ascending dose clinical trial in healthy volunteers.
The new clinical trial is designed to look at more frequent daily dosing (twice and three times daily) of fezagepras up to 2,400mg for a total of 14 days. The clinical trial is a standard placebo-controlled Phase 1 ascending dose design in healthy volunteers. The clinical trial endpoints will include safety, pharmacokinetics, and exploratory biomarkers related to the mechanism of action of fezagepras. The data from this clinical trial will be used to guide selection of the app
Pakistan may introduce C-IVIG therapy as Covid continue to spread
73 die of deadly contagion as 2,459 more test positive
A paramedic wearing protective gloves prepares to take a blood sample from a woman, to be tested for the coronavirus disease (COVID-19) anti-body test, at a camp in Karachi. PHOTO: REUTERS/FILE
ISLAMABAD:
Pakistan is on the threshold of becoming the first country to carry out research, mandatory to introduce intravenous immunoglobulin (C-IVIG) therapy at a mass level as ‘severe’ patients under treatment for coronavirus, have 100% recovery rate.
Scientists at the Dow University of Health Sciences (DUHS) in Karachi, who are conducting clinical trials of the C-IVIG therapy for the treatment coronavirus, have said that the trials were very encouraging and remarkable.